Holen Sie sich die Stockscreener-App
2.089
0.54%
0.019
Schlusskurs vom Vortag:
$2.07
Offen:
$2.07
24-Stunden-Volumen:
5,819
Relative Volume:
0.04
Marktkapitalisierung:
$4.54M
Einnahmen:
$10.48M
Nettoeinkommen (Verlust:
$-37.74M
KGV:
-0.1291
EPS:
-16.1846
Netto-Cashflow:
$-29.03M
1W Leistung:
-4.97%
1M Leistung:
+6.18%
6M Leistung:
-62.64%
1J Leistung:
-93.34%
1-Tages-Spanne:
$2.07
$2.1246
1-Wochen-Bereich:
$1.93
$2.415
52-Wochen-Spanne:
$1.5701
$33.25
Jaguar Health Inc Stock (JAGX) Company Profile
Firmenname
Jaguar Health Inc
Sektor
Branche
Telefon
415-371-8300
Adresse
200 PINE STREET SUITE 400, SAN FRANCISCO, CA
Vergleichen Sie JAGX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
JAGX
Jaguar Health Inc
|
2.087 | 7.67M | 10.48M | -37.74M | -29.03M | -16.18 |
|
VRTX
Vertex Pharmaceuticals Inc
|
406.28 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.63 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
550.19 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
800.57 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
328.93 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Jaguar Health Inc Stock (JAGX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-07-07 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2017-07-11 | Eingeleitet | Rodman & Renshaw | Buy |
Jaguar Health Inc Aktie (JAGX) Neueste Nachrichten
Will Jaguar Health Inc. stock pay special dividends2025 Key Lessons & Free Reliable Trade Execution Plans - newser.com
FDA-Authorized Expanded Access Programs Utilizing Jaguar Health's Novel Crofelemer Powder for Oral Solution to Treat Two Pediatric Intestinal Failure Patients with Microvillus Inclusion Disease - Worcester Telegram
Evaluating Jaguar Health Inc. with trendline analysis2025 Market Outlook & Daily Stock Momentum Reports - newser.com
Analyzing Jaguar Health Inc. with risk reward ratio chartsJuly 2025 Reactions & Consistent Income Trade Recommendations - newser.com
Price action breakdown for Jaguar Health Inc.Quarterly Profit Summary & Reliable Intraday Trade Alerts - newser.com
Jaguar Health Presenting September 25 at Emerging Growth Conference and September 30 at Lytham Partners Fall 2025 Conference to Provide Updates on Near-Term Catalysts - Lansing State Journal
Jaguar Health Presenting at September 8-10 H.C. Wainwright Annual Global Investment Conference to Provide Updates on Near-Term Catalysts - Peoria Journal Star
Jaguar Health Submits Orphan Drug Designation Application to FDA for Crofelemer for Cancer Therapy-Related Diarrhea (CTD) in Patients with Breast Cancer with Metastasis Identified by FDA as a Distinct Condition - Shreveport Times
Using fundamentals and technicals on Jaguar Health Inc.Exit Point & High Win Rate Trade Alerts - newser.com
Chart based analysis of Jaguar Health Inc. trendsQuarterly Trade Review & Stock Market Timing Techniques - newser.com
Published on: 2025-10-10 04:56:36 - newser.com
Real time social sentiment graph for Jaguar Health Inc.New Guidance & AI Driven Stock Movement Reports - newser.com
What machine learning models say about Jaguar Health Inc.July 2025 Trade Ideas & AI Powered Market Entry Ideas - newser.com
Momentum divergence signals in Jaguar Health Inc. chartWatch List & Free Verified High Yield Trade Plans - newser.com
FDA Approves Renewal of Canalevia-CA1, Jaguar Health’s Drug for Chemotherapy-Induced Diarrhea in Dogs - ACCESS Newswire
How to build a custom watchlist for Jaguar Health Inc.New Guidance & Long-Term Safe Investment Plans - newser.com
Tools to assess Jaguar Health Inc.’s risk profile2025 Bull vs Bear & Growth Focused Entry Point Reports - newser.com
Jaguar Health registers 2.62M shares for resale following private placements - MSN
Jaguar Health Announces New Employee Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - ACCESS Newswire
Jaguar Health Completes Meeting with FDA for Advice on Development Pathways to Advance Ongoing Crofelemer Trial for Potential Approval for Treatment of Pediatric Indication Microvillus Inclusion Disease (MVID) - The Florida Times-Union
Jaguar Health reports positive results in MVID treatment trial By Investing.com - Investing.com Nigeria
Jaguar Health reports positive results in MVID treatment trial - Investing.com
Jaguar Health (JAGX) Advances Crofelemer Trial Following FDA Mee - GuruFocus
37% PS reduction; Jaguar Health's crofelemer powder reduced TPN 30% in pediatric MVID trial - Stock Titan
Is Jaguar Health Inc. stock a buy before product launchesWeekly Volume Report & Low Risk Entry Point Tips - newser.com
Can technical indicators confirm Jaguar Health Inc.’s reversalJuly 2025 EndofMonth & Low Risk Entry Point Tips - newser.com
Finanzdaten der Jaguar Health Inc-Aktie (JAGX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.11%
2.69%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):